UK Chorea Market

ID: MRFR/HC/51938-HCR
200 Pages
Vikita Thakur
Last Updated: February 06, 2026
UK Chorea Market Research Report By Distribution Channel (hospitals, clinics, diagnostic centers, drug stores, pharmacies, others), By Symptoms (involuntary muscle movements, milkmaid's grip, speech problems, seizures), By End User (clinics, hospitals, ambulatory surgical centers, others), By Product Type (Medication, Surgery therapy) and By Treatment (Medical care, Surgical care) -Forecast to 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Chorea Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)6.46%
2024 Market Size$ 36 Million
2025 Market Size$ 38.33 Million
2035 Market Size$ 71.66 Million

Key Players

Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb Company
AbbVie Inc
Novartis AG
Roche Holding AG
Sanofi
Trends
  • Rising Awareness and Education
  • Advancements in Treatment Options
  • Technological Integration in Care
Opportunities
  • Advancements in Genetic Research
  • Government Initiatives and Funding
  • Emerging Pharmaceutical Innovations
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Security, Access Control and Robotics, BY Type (USD Million)
      1. 4.1.1 Huntington's disease
      2. 4.1.2 Rheumatic (Sydenham's Chorea)
      3. 4.1.3 Drug-induced Chorea
    2. 4.2 Security, Access Control and Robotics, BY Treatment (USD Million)
      1. 4.2.1 Medical care
      2. 4.2.2 Surgical care
    3. 4.3 Security, Access Control and Robotics, BY Distribution Channel (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Clinics
      3. 4.3.3 Diagnostic centers
      4. 4.3.4 Drug stores
      5. 4.3.5 Pharmacies
      6. 4.3.6 Others
    4. 4.4 Security, Access Control and Robotics, BY Symptoms (USD Million)
      1. 4.4.1 Involuntary muscle movements
      2. 4.4.2 Milkmaid's grip
      3. 4.4.3 Speech problems
      4. 4.4.4 Seizures
    5. 4.5 Security, Access Control and Robotics, BY End-Users (USD Million)
      1. 4.5.1 Clinics
      2. 4.5.2 Hospitals
      3. 4.5.3 Ambulatory surgical centers
      4. 4.5.4 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Teva Pharmaceutical Industries Ltd (IL)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb Company (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AbbVie Inc (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis AG (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Roche Holding AG (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Sanofi (FR)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Pfizer Inc (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Eli Lilly and Company (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 AstraZeneca PLC (GB)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY TYPE
    3. 6.3 UK MARKET ANALYSIS BY TREATMENT
    4. 6.4 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    5. 6.5 UK MARKET ANALYSIS BY SYMPTOMS
    6. 6.6 UK MARKET ANALYSIS BY END-USERS
    7. 6.7 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
    10. 6.10 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    12. 6.12 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
    13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 (% SHARE)
    14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 TO 2035 (USD Million)
    15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 (% SHARE)
    16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 TO 2035 (USD Million)
    17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY SYMPTOMS, 2024 (% SHARE)
    20. 6.20 SECURITY, ACCESS CONTROL AND ROBOTICS, BY SYMPTOMS, 2024 TO 2035 (USD Million)
    21. 6.21 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USERS, 2024 (% SHARE)
    22. 6.22 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USERS, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.2.4 BY SYMPTOMS, 2025-2035 (USD Million)
      5. 7.2.5 BY END-USERS, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Type (USD Million, 2025-2035)

  • Huntington's disease
  • Rheumatic (Sydenham's Chorea)
  • Drug-induced Chorea

Security, Access Control and Robotics By Treatment (USD Million, 2025-2035)

  • Medical care
  • Surgical care

Security, Access Control and Robotics By Distribution Channel (USD Million, 2025-2035)

  • Hospitals
  • Clinics
  • Diagnostic centers
  • Drug stores
  • Pharmacies
  • Others

Security, Access Control and Robotics By Symptoms (USD Million, 2025-2035)

  • Involuntary muscle movements
  • Milkmaid's grip
  • Speech problems
  • Seizures

Security, Access Control and Robotics By End-Users (USD Million, 2025-2035)

  • Clinics
  • Hospitals
  • Ambulatory surgical centers
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035